93 results on '"Daratumumab"'
Search Results
2. Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis
3. A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India
4. Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma
5. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
6. TEMPI syndrome: difficult to diagnose, “easy” to treat?
7. Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma
8. Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain
9. Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab
10. Proliferative glomerulonephritis with monoclonal IgG deposits in an adolescent successfully treated with daratumumab
11. Daratumumab for De-sensitization of Donor Specific Antibodies: Is it a Quicker and Easier way?
12. Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
13. Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
14. Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study
15. Daratumumab therapy in a pediatric case of C3 nephritic factor-positive proliferative glomerulonephritis with monoclonal IgG deposits
16. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study
17. Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
18. Non-producer multiple myeloma presenting with acute hyperammonemic encephalopathy: case report
19. Pomalidomide combinations are a safe and effective option after daratumumab failure
20. Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment
21. Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
22. Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
23. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
24. Lessons for the clinical nephrologist: a rare case with MGRS characterized by combined crystalline light chain proximal tubulopathy and crystal-storing histiocytosis responding to daratumumab
25. Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
26. Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpura
27. High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
28. Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
29. Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
30. Monoclonal antibody Daratumumab promotes macrophage-mediated anti-myeloma phagocytic activity via engaging FC gamma receptor and activation of macrophages
31. Immunotherapy in AL Amyloidosis
32. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment
33. Multiple myeloma with central nervous system relapse: a case report
34. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma
35. Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma
36. 64Cu-labeled daratumumab F(ab′)2 fragment enables early visualization of CD38-positive lymphoma
37. Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany
38. Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report
39. Expanding anti-CD38 immunotherapy for lymphoid malignancies
40. Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
41. Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy
42. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial
43. Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis
44. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
45. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053
46. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study
47. Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
48. Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy
49. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
50. A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.